Vaxart (NASDAQ:VXRT) Stock Price Passes Below 200 Day Moving Average – Time to Sell?

Vaxart, Inc. (NASDAQ:VXRT)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.78 and traded as low as $0.76. Vaxart shares last traded at $0.77, with a volume of 1,120,717 shares trading hands.

Analysts Set New Price Targets

Separately, Oppenheimer assumed coverage on Vaxart in a research note on Thursday, August 15th. They set an “outperform” rating and a $4.00 target price on the stock.

Vaxart Stock Down 2.5 %

The company’s fifty day moving average is $0.85 and its 200-day moving average is $0.78. The company has a market cap of $135.33 million, a PE ratio of -1.44 and a beta of 0.66.

Vaxart (NASDAQ:VXRT) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.12). The business had revenue of $6.40 million for the quarter, compared to the consensus estimate of $65.70 million. Vaxart had a negative net margin of 543.21% and a negative return on equity of 114.19%. During the same quarter last year, the firm posted ($0.16) earnings per share. Equities research analysts expect that Vaxart, Inc. will post -0.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Tidal Investments LLC purchased a new stake in shares of Vaxart in the first quarter worth $56,000. Sequoia Financial Advisors LLC purchased a new stake in shares of Vaxart in the second quarter worth about $65,000. Monaco Asset Management SAM bought a new position in shares of Vaxart during the 2nd quarter valued at approximately $402,000. Vanguard Group Inc. increased its position in shares of Vaxart by 19.9% during the 1st quarter. Vanguard Group Inc. now owns 8,449,362 shares of the biotechnology company’s stock valued at $10,984,000 after purchasing an additional 1,404,391 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in Vaxart by 110.8% during the 2nd quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock valued at $2,660,000 after purchasing an additional 2,095,274 shares during the last quarter. 18.05% of the stock is owned by hedge funds and other institutional investors.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.